拉米夫定耐药与HBV YMDD变异关系的研究

To detect YMDD mutations of HBV by gene chips in patient with chronic hepatitis B treated with lamivudine and to evaluate its clinic importance. Sera of 102 patients with chronic hepatitis B treated with lamivudine 9-30 months were detected for ALT、HBV makers、YMDD mutation. In 102 patients, HBV DNA turned negative in 63 cases (61.8%) , 22 cases of YMDD mutations among 39 patients (56.4%) , its rate increasing with length of lamivudine treatment as rate was 51.7% between 9-17 months and rate 70% between 18-30 months. ALT level in patients with YMDD mutation was significant higher than the groups without YMDD mutation (59.94±8.60) U/L vs (50.60±6.12) U/L, P<0.05. Gene chips can be applied to identifying HBV YMDD mutant clinically; YMDD mutation is one of the reason that HBV resistant to lamivudine and may lead to elevation of ALT.